Study of SHEN26 Capsule in Patients With Mild to Moderate COVID-19

Summary

This is a multicenter, randomized, double-blind, placebo-parallel-controlled phase II clinical trial. It is designed to evaluate the efficacy, safety, tolerability, and pharmacokinetic (PK) profile of SHEN26 capsules in Chinese patients with mild to moderate COVID-19.

Timeline

Start

2022-12-08

Primary completion

2022-12-30

Completion

2023-01-27

Publications

• Bai J, Asakawa T, Yuan W, Lin Y, Ju H, Xu D, Yang M, Li S, Li G, Guo D, Lu H, Zhang X. Efficacy and safety of SHEN26, a novel oral small molecular RdRp inhibitor for COVID-19 treatment: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial. Virol J. 2025 Jan 25;22(1):16. doi: 10.1186/s12985-025-02631-y.

Drugs

Indications